Tags : Auto-Immune Diseases

Bio Thera’s QLETLI (biosimilar, adalimumab) Receives NMPA’s Approval for Auto-Immune

Shots: The approval of QLETLI is based on P-III study resulted in meeting its 1EPs, demonstrating bio-similarity to the reference product, Humira (adalimumab) including clinical/nonclinical, PK/PD data The approval of QLETLI marks the first approval in a regulated market from Bio Thera’s biosimilar portfolio and is the second biosimilar to be approved by NMPA QLETLI […]Read More